MedTrace Logo

Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT03047473 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-05-25

Study results available
· View outcomes & findings →

Summary

This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme.

All patients will be receiving active therapy. Patients will begin the avelumab within 3 weeks of finishing their radiotherapy. Avelumab will be given at a dose of 10mg/kg IV every 2 weeks concomitantly with the monthly temozolomide. Avelumab will be continued for a total of 52 weeks.

Conditions

  • Glioblastoma Multiforme of Brain

Interventions

BIOLOGICAL

avelumab

add on of avelumab 10mg/kg IV to standard therapy

Sponsors & Collaborators

  • Clinique Neuro-Outaouais

    lead OTHER

Principal Investigators

  • François Jacques, MD · Clinique Neuro-Outaouais

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-19
Primary Completion
2021-08-09
Completion
2021-08-09
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03047473 on ClinicalTrials.gov